Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Simeng Lin
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Research in context Evidence before this study The patient, disease, and pharmacokinetic factors implicated in anti-TNF treatment failure and loss of response remain poorly elucidated, in particular over the longer term.
Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
Abstract : Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD, yet many patients do not adequately respond to such therapy. Previous studies have demonstrated a pro-inflammatory pattern in the composition of CD patients’ immunoglobulin G (IgG) N-glycome compared to healthy individuals.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Abstract Objective Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 antibody responses and protective immunity in infliximab-treated patients with IBD.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Interpretation In keeping with the original vaccine trials,22 23 after two vaccine doses, the highest anti-S RBD antibody concentrations were observed in recipients of the BNT162b2 vaccine.
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Outcomes of COVID-19 in patients with IBD Over the course of the pandemic, the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) international registry has helped clinicians and patients better understand outcomes of COVID-19 in patients with IBD.
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Effect of IBD drugs on COVID-19 outcome Systemic steroids Throughout the pandemic, there was extensive evidence demonstrating the detrimental effect of systemic steroids on clinical outcomes of patients with IBD who developed COVID-19. However, most published data are subject to unmeasured confounding between IBD activity, COVID-19 severity and concomitant steroid use.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Inflammatory bowel disease Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD Free http://orcid.org/0000-0003-4368-1961Nicholas A Kennedy1,2, http://orcid.org/0000-0002-4201-4879Simeng Lin1,2, http://orcid.org/0000-0003-3112-376XJames R Goodhand1,2, http://orcid.org/0000-0003-0207-6706Neil Chanchlani1,2, http://orcid.org/0000-0002-0349-278XBenjamin Hamilton1,2, http://orcid.org/0000-0002-0965-9587Claire Bewshea2,...
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Inflammatory bowel disease Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD Free http://orcid.org/0000-0003-4368-1961Nicholas A Kennedy1,2, http://orcid.org/0000-0002-4201-4879Simeng Lin1,2, http://orcid.org/0000-0003-3112-376XJames R Goodhand1,2, http://orcid.org/0000-0003-0207-6706Neil Chanchlani1,2, http://orcid.org/0000-0002-0349-278XBenjamin Hamilton1,2, http://orcid.org/0000-0002-0965-9587Claire Bewshea2,...
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Inflammatory bowel disease Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD Free http://orcid.org/0000-0003-4368-1961Nicholas A Kennedy1,2, http://orcid.org/0000-0002-4201-4879Simeng Lin1,2, http://orcid.org/0000-0003-3112-376XJames R Goodhand1,2, http://orcid.org/0000-0003-0207-6706Neil Chanchlani1,2, http://orcid.org/0000-0002-0349-278XBenjamin Hamilton1,2, http://orcid.org/0000-0002-0965-9587Claire Bewshea2,...
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines
Nicholas A Kennedy, Simeng Lin, James R Goodhand, Neil Chanchlani, Ben Hamilton, Claire Bewshea, Rachel Nice, Desmond Chee, JR Fraser Cummings, Aileen Fraser, Peter M Irving, Nikolaos Kamperidis, Klaartje B Kok, Christopher A Lamb, Jonathan Macdonald, Shameer J Mehta, Richard CG Pollok, Tim Raine, Philip J Smith, Ajay M Verma, Timothy J McDonald, Shaji Sebastian, Charlie W Lees, Nick Powell, Tariq Ahmad, Contributors to the CLARITY IBD study doi: https://doi.org/10.1101/2021.03.25.21254335...
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines
Abstract Background Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single-dose of a SARS-CoV-2 vaccine.
Quality improvement project identifies factors associated with delay in IBD diagnosis
1 INTRODUCTION Delay in the diagnosis of inflammatory bowel disease (IBD), in particular Crohn's disease, is common.
Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study
Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study http://orcid.org/0000-0002-3883-8816Gareth J Walker1,2, http://orcid.org/0000-0003-0207-6706Neil Chanchlani2,3, Amanda Thomas1,2, http://orcid.org/0000-0002-4201-4879Simeng Lin1,2, Lucy Moore4, http://orcid.org/0000-0003-0579-2062Neel M Heerasing1,2, Peter Hendy1,2, Mohamed Abdelrahim1, Sean Mole1, Mandy H Perry5, http://orcid.org/0000-0003-3559-6660Timothy J...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Simeng
Contact Simeng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack